Sqz Biotechnologies Company · OTC:SQZB
Sqz Biotechnologies — ESMO-IO 2021
10 slides from Sqz Biotechnologies's conference presentation, Dec 9, 2021
Slide 1: Preliminary results of a first-in-human, dose-escalation study of a cell-based vaccine
Preliminary results of a first-in-human, dose-escalation study of a cell-based vaccine in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors SQZ-PBMC-HPV-101: Jong Chul Park, Joaquina Baranda, Monica Mita, Wade T Iams, Michael S Gordon, Matthew Taylor, Neesha Dhan
Slide 2: Declaration of Interest
Declaration of Interest Consulting and Advisory Role: ALB, Merck, I-Mab, Mito Research funding: ALX (Inst), Inhibrx (Inst), Merck (Inst), Monopteros (Inst), Novartis (Inst), Oncorus (Inst), SQZ (Inst) Jong Chul Park
Slide 3: SQZ-PBMC-HPV-101: Underlying Technology and Mechanism
SQZ-PBMC-HPV-101: Underlying Technology and Mechanism Prior cancer vaccines relied on cross-presentation, resulting in ineffective MHC-I presentation to CD8 T cells, limiting T cell activation and efficacy. Squeezed Antigen MHC-I = CD8 T Cell Activation SQZTM APC Mechanism: Direct Presentation Typic
Slide 4: Study Design and Cell Therapy Production
Study Design and Cell Therapy Production Cell Therapy Production Monotherapy Escalation Combination De-escalation Recurrent or metastatic HPV-driven cancer HPV-16+ HLA-A *02+ Platinum experienced CPI offered Inclusion Criteria Treatment until PD, unacceptable toxicity or 2 years SQZ-PBMC-HPV 5.0e6/k
Slide 5: SQZ-PBMC-HPV Evaluated in Advanced Patient Population
SQZ-PBMC-HPV Evaluated in Advanced Patient Population Characteristic 0.5 M cells/kg SP (n=3) 2.5 M cells/kg SP (n=5) 2.5 M cells/kg DP (n=4) 5.0 M cells/kg DP (n=6) Total (n=18) Median Age, years (min, max) 65 (60, 68) 65 (54, 68) 49 (47, 66) 57.5 (52, 78) 60 (47, 78) Female, n (%) 3 (100) 3 (60) 3
Slide 6: SQZ-PBMC-HPV Was Considered Safe and Well-Tolerated
SQZ-PBMC-HPV Was Considered Safe and Well-Tolerated Event, n (%) 0.5 M cells/kg SP (n=3) 2.5 M cells/kg SP (n=5) 2.5 M cells/kg DP (n=4) 5.0 M cells/kg DP (n=6) Total (n=18) Related AEs in >1 Patient 3 (100) 4 (80) 2 (50) 5 (83) 14 (78) Fatigue 0 1 (20) 0 4 (67) 5 (28) Flushing 1 (33) 0 0 2 (33) 3 (
Slide 7: Potential Proof-of-Concept for SQZ-PBMC-HPV in anti-PD-1 Refractory Patient
Potential Proof-of-Concept for SQZ-PBMC-HPV in anti-PD-1 Refractory Patient 52-year-old man with squamous cell carcinoma of the oropharynx. Large primary lesion with significant symptoms burden. Initial diagnosis 3.7 years ago, with 6 prior lines of systemic therapy including carbo/5FU/pembro and an
Slide 8: SQZ-PBMC-HPV Turns TME into Inflamed Phenotype in Responding Patient
SQZ-PBMC-HPV Turns TME into Inflamed Phenotype in Responding Patient Massive influx of CD8 cells into the tumor changed immunophenotype from desert to inflamed. Increase in HLA-I expression likely due to CD8 driven IFN-γ secretion. Significant reduction in frequency of E6 expressing cells as measure
Slide 9: Conclusions and Future Development for SQZ-PBMC-HPV
Conclusions and Future Development for SQZ-PBMC-HPV Future Development SQZ-PBMC-HPV at 5.0M cells/kg dose was endorsed by study DSMB to move into PD-(L)1 & CTLA-4 combination cohorts. The highest dose cohort is still enrolling to further characterize efficacy of SQZ-PBMC-HPV as monotherapy. Conclusi
Slide 10: We thank the patients and their families!
We thank the patients and their families! Additional information may be found at: